Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for PhoenixBio Co., Ltd. (6190:JPX), powered by AI.
PhoenixBio Co., Ltd. is currently trading at ¥484. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for PhoenixBio Co., Ltd. on Alpha Lenz.
PhoenixBio Co., Ltd.'s P/E ratio is -4.4.
“PhoenixBio Co., Ltd. trades at a P/E of -4.4 (undervalued) with modest ROE of -28.4%.”
Ask for details →PhoenixBio Co., Ltd. is a biotechnology company dedicated to the development of cutting-edge bio-research products. The primary focus of PhoenixBio is on creating and distributing high-quality human liver-based research tools and technology platforms. These products are essential for pharmaceutical companies and research institutions engaged in drug discovery and development, particularly in areas like toxicology and pharmacology where precise human liver models can significantly impact research outcomes. With a commitment to innovation, PhoenixBio primarily serves the scientific and medical research communities, facilitating advancements in understanding liver diseases and their treatments. Located in Japan, PhoenixBio has carved out a significant niche by offering proprietary bioengineered models that simulate human liver functions, thus enhancing the drug discovery process. Its role in the market is crucial, acting as a bridge between pure scientific research and practical applications in medicine, particularly in developing safer and more efficient pharmaceuticals.
“PhoenixBio Co., Ltd. trades at a P/E of -4.4 (undervalued) with modest ROE of -28.4%.”
Ask for details →